Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-029-1 | CAS number: 113-48-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- October 1989 to December 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
- Report date:
- 1991
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 83-1 (Chronic Toxicity)
- GLP compliance:
- yes
Test material
- Reference substance name:
- N-(2-ethylhexyl)-8,9,10-trinorborn-5-ene-2,3-dicarboximide
- EC Number:
- 204-029-1
- EC Name:
- N-(2-ethylhexyl)-8,9,10-trinorborn-5-ene-2,3-dicarboximide
- Cas Number:
- 113-48-4
- Molecular formula:
- C17H25NO2
- IUPAC Name:
- N-(2-ethylhexyl)-8,9,10-trinorborn-5-ene-2,3-dicarboximide
- Reference substance name:
- (E)-1,4-Bis(2-ethylhexylamino)-2-butene-1,4-dione
- Molecular formula:
- C20H38N2O2
- IUPAC Name:
- (E)-1,4-Bis(2-ethylhexylamino)-2-butene-1,4-dione
- Reference substance name:
- 1-(2-ethylhexyl)-1H-pyrrole-2,5-dione
- Molecular formula:
- C12H19NO2
- IUPAC Name:
- 1-(2-ethylhexyl)-1H-pyrrole-2,5-dione
- Test material form:
- liquid
- Details on test material:
- Purity and characterisation analysis conducted on the following sample; Supplier: McLaughlin Gormley King ; Batch Number: AB9500
Constituent 1
impurity 1
impurity 2
- Specific details on test material used for the study:
- MGK 264 Lot 7437, pale yellow viscous liquid was received at the experimental laboratory on 10/04/1988 in 2 drums. The test material was provded by the Sponsor. The test material was stored at rom temperature under environmentally controlled conditions. Samples of the test material were collected at 6 month intervals and sent back to the sponsor for analysis.
Test animals
- Species:
- dog
- Strain:
- Beagle
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Twenty (20) male and 20 female purebred beagle dogs (approximately
3 1/2 to 4 1/2 months of age) were obtained from Ridglan
Farms, Inc., Mount Horeb, Wisconsin on September 13, 1989. A few of
the animals were slightly younger than the 4 months of age required
by the protocol at receipt. In the opinion of the Study Director
this protocol deviation did not affect the quality or the intgrity
of the study. The dogs were immunized against distemper, parvovirus,
parainfluenza, adenovirus type 2, Bordetella, leptospirosis
and rabies by the breeder prior to receipt at IRDC. Flotation tests
were conducted on stool samples obtained from each dog; the results
of the tests were negative.
At various intervals during the study, otitis was
noted for a few dogs in the control and treated groups; the appropriate
treatments were performed. Clinical pathology and ophthalmological
examinations were conducted on each dog prior to study
initiation. From these animals, sixteen males (weighing from 8.9 to
14.8 kg) and sixteen females (weighing from 9.1 to 11.8 kg) were selected
on the basis of best physical condition. The 16 dogs of each
sex were assigned at random to control or treated groups.
The dogs were individually housed in stainless steel cages
equipped with automatic watering valves and maintained in an environmentally
controlled room with a 12 hour light/12 hour dark cycle.
The temperature and humidity were continuously recorded and the recordings
were monitored for conformance with protocol specifications.
Appropriate corrective action was taken whenever readings
were outside acceptable limits. On some occasions the results of
the environmental monitoring and/or documentation of corrective
action(s) were inadvertently not recorded. In the opinion of the
Study Director, these protocol deviations did not affect the quality
or the integrity of the study. The graphs of temperature and humidity
are maintained in the study records.
Administration / exposure
- Route of administration:
- oral: feed
- Details on route of administration:
- A potential route of administration to humans is oral.
Therefore, this study employed the oral route. - Vehicle:
- other: Premixed with Certified Canine Diet #5007, Purina Mills, Inc., St. Louis, Missouri
- Details on oral exposure:
- Route: via diet
Frequency of Administration: continuously in the diet
Preparation of Diet Mixtures: at least once weekly
Storage of Diet Mixtures: room temperature
Diet Mixtures Stable for a Period of: 21 days - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- For Determination of Test Article Concentration throughout the study, 100 gram samples were taken from
the top, middle and bottom of each diet at the time test article:diet mixtures were prepared. The three samples (top, middle and bottom) were mixed to form a composite sample, which was then subdivided into three 100 gram samples. For study weeks 1-4 and every
four weeks thereafter, one set of these triplicate samples was analyzed in duplicate for determination of test article concentration
Duplicate 10g subsamples were extracted by petroleum ether using Soxhlet equipment and dose concentrations quantified by GC. The other two sets were stored frozen. At all other study weeks all three sets of samples were stored frozen. - Duration of treatment / exposure:
- MGK® 264 was offered in the diet to beagle dogs at constant concentrations of 65, 250 and 1,000 ppm for
one year; a control group received ground diet on the same regimen. - Frequency of treatment:
- food available ad libitum, except prior to clinical pathology testing and necropsy.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 65 ppm
- Dose / conc.:
- 250 ppm
- Dose / conc.:
- 1 000 ppm
- No. of animals per sex per dose:
- 4 female/ 4 male
- Control animals:
- yes, plain diet
- Details on study design:
- MGK® 264 was offered in the diet to beagle dogs at constant concentrations of 65, 250 and 1,000 ppm for
one year; a control group received ground diet on the same regimen. Four male and four female dogs were initiated on study for each of the four groups.
Examinations
- Observations and examinations performed and frequency:
- Mortality, moribundity and overt toxicity at least twice daily; detailed observations at least once each.
Bodyweights determined pre-test and weekly thereafter.
Food consumption determined weekly.
Ophthalmoscopic examinations carried out pretest, 12, 24 and 51 weeks of study.
On all dogs pretest and at 6, 12, 25 and 50 weeks of study:
Hematocrit; hemoglobin; erythrocyte count; mean corpuscular hemoglobin (MCH), volume (MCV), and hemoglobin concentration (MCHC); total and differential leukocyte counts; platelets; reticulocytes.
Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, leucine aminopeptidase, glucose, urea nitrogen, total bilirubin, cholesterol, albumin, globulin (calculated), albumin/globulin ratio (calculated), total prote1n,
creatinine, inorganic phosphate, creatine phosphokinase, sodium, potassium, chloride, calcium. Volume, color and appearance, pH, specific gravity, protein, glucose, ketones, urobilinogen, nitrite, bilirubin, leucocytes, occult blood, microscopic element. - Sacrifice and pathology:
- Anatomic pathology on all surviving animals at study week 52. Tissues fixed in formalin (except eye, in a glutaraldehyde fixative, and testis and epididymis in Bouin's_ fixative). Bone marrow smears collected at.terminal sacrifice. Organ weights taken for all dogs sacrificed at study termination. Absolute and relative (to body and brain weights) weights of liver, kidney (2), heart, spleen, testis (2), brain, ovary (2), pituitary, thyroid/parathyroid (2), adrenal (2). Tissues examined: Adrenal (2), aorta, bone (rib), bone marrow (rib), brain (fore, mid and hind), eye including optic nerve (2), gallbladder, esophagus, stomach (glandular and nonglandular), duodenum,
jejunum, ileum, cecum, colon, rectum, ovary (2), testis with epididymis (2), heart, kidney (2), liver (3 sections), lung with mainstem bronchi (2), lymph nodes (tracheobronchial, mesenteric), mammary gland (female only), pancreas, pituitary, prostate, salivary gland
(mandibular with mandibular lymph node), sciatic nerve, skeletal muscle (thigh), skin, spinal cord (cervical, (mid)thoracic and lumbar), spleen, thymus, thyroid/parathyroid (2), trachea, urinary bladder, uterus, vagina, gross lesions, animal identification site.
Microscopic pathology examined on all dogs. Tissues sectioned at 5 microns and stained with hematoxylin and eosin. - Statistics:
- Body weights, food consumption values, clinical pathology parameters and organ weights analyzed using analysis of variance and Bartlett's test. Treatment groups compared to the control group, by sex, using the
appropriate t-statistic (equal or unequal variance). Nonparametric analysis, when appropriate, by rank transformation.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No adverse effects were found during the study. In general animals receiving MGK 264 gained more weight than control animals especially in male animals.
- Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- In general, the g/animal/day food consumption of the dogs in the treated groups was increased compared to that of the control
dogs, with the difference statistically significant in isolated instances.
However, these increases did not occur in a dose-related pattern. Similarly, the g/kg/day food consumption of the treated females was increased, although not in a dose-related fashion, during the first 6 months of the study. During the latter half of the study, the values for this parameter were comparable for the control and treated females. The q/kg/day food consumption of the treated males fluctuated in relation to the control values; no dose-related or statistically significant differences were observed. - Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test substance related organ weight variations were discerned in any of the experimental groups. A number of statistically significant variations occurred but these were considered to reflect normal biological variation because there was no dose response or correlation with any morphologic changes.
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Test substance related microscopic findings were limited to the liver of male and female dogs from the 1,000 ppm group. Brown pigment considered to represent biliary stasis, because of its apparent intracanalicular location and its deep, reddish brown color (which was characteristic of bile) was present for the majority of the dogs in this group. Two male dogs from the 1,000 ppm group also had
trace hepatocellular hypertrophy which was also considered test substance related.Note that these findings in the liver were not associated with degenerative change. - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- no effects observed
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 ppm
- Based on:
- other: MGK 264 in the diet equivalent to 34.9/32.5 mg/kg bw/day in males/females
- Sex:
- male/female
- Basis for effect level:
- histopathology: non-neoplastic
Target system / organ toxicity
- Key result
- Critical effects observed:
- not specified
- Lowest effective dose / conc.:
- 1 000 ppm
- System:
- hepatobiliary
- Organ:
- liver
Applicant's summary and conclusion
- Conclusions:
- In summation, MGK® 264 was offered in the diet to beagle dogs at constant concentrations of 65, 250 and 1,000 ppm for one year; a control group received ground diet on the same regimen.
Four male and four female dogs were initiated on study for each of the four groups.
MGK® 264 induced microscopic changes of brown pigment in the liver and trace hepatocellular hypertrophy when offered in the diet at a concentration of 1,000 ppm to beagle dogs for one year. No other changes were observed that could be related to treatment with the test substance. The no-observed-effect-level (NOEL) dose concentration was considered to be 250 ppm in the diet which was equivalent to 7.5 mg/kg bw/day in males and 7.4 mg/kg bw/day in females based on average compound consumption.
However, these changes suggested that the liver was involved in the metabolism and excretion of the test substance. Trace hepatocellular hypertrophy and cytoplasmic pigment in some animals reflected the additional work load as a consequence of ingestion of large quantities of test substance. Degenerative changes were not identified. Therefore, in the absence of degenerative changes occurring in the liver the systemic no-observed-adverse-effect-level (NOAEL) is 1000 ppm equivalent to 34.9/32.5 mg/kg bw/day in males/females. - Executive summary:
A one year dietary administration study of MGK 264 was performed in dogs according to EPA OPP 83 -1 (chronic toxicity).
MGK® 264 was offered in the diet to beagle dogs at constant concentrations of 65, 250, and l,000 ppm for one year. A control group received ground diet on the same regimen. During the study twice daily observations of mortality/moribundity and overt toxicity were performed. The dogs were weighed weekly and the food consumed was measured weekly. Ophthalmoscopic examinations of the eyes were performed pre-trial and again at weeks 12, 24 and 51. Clinical pathology examinations were performed pre-trial and at weeks , 12, 25 and 50. At the end of the treatment period the animals were sacrificed and necropsy examinations performed. Selected tissues were weighed and a full list of tissues processed for microscopic examination.
All dogs survived the treatment period. No adverse effects were recorded for clinical signs, body weight, food intake, clinical pathology, macroscopic findings or organ weight. Microscopic findings of cytoplasmic pigment possibly indicating biliary stasis, was noted in the livers of the 1000 ppm males and females. In addition there was trace hepatocellular hypertrophy in 2 of the 4 males from this group. None of these changes were associated with degenerative conditions.
On the basis of the findings in the liver, the NOEL was considered to be 250 ppm which is equivalent to 7.5 mg/kg bw/day in males and 7.4 mg/kg bw/day in females based on average compound consumption. However, these changes suggested that the liver was involved in the metabolism and excretion of the test substance.Trace hepatocellular hypertrophy and cytoplasmic pigment in some animals reflected the additional work load as a consequence of ingestion of large quantities of test substance.Degenerative changes were not identified.Therefore, in the absence of degenerative changes occurring in the liver the systemic no-observed-adverse-effect-level (NOAEL) is 1000 ppm equivalent to 34.9/32.5 mg/kg bw/day in males/females.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.